# Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma

> **NCT07632339** · PHASE2 · RECRUITING · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 102 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Becotatug Vedotin combined with Pucotenlimab
- **PROCEDURE:** surgery

## Key facts

- **NCT ID:** NCT07632339
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-16
- **Primary completion:** 2028-06-16
- **Final completion:** 2029-06-16
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07632339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07632339, "Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07632339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*